Double-Barreled CAR-T attack on Hard-to-Treat myeloma
NCT ID NCT07003555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has returned or not responded to treatment and has spread outside the bone marrow. The main goal is to check the safety of this approach in up to 18 adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Liquan Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
- New antibody drug aims to outsmart Treatment-Resistant myeloma
- New hope for Tough-to-Treat blood cancer: phase 3 trial launched
- New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma
- Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
- New antibody drug tested for tough blood cancers – but trial stopped early